The equity analysts at TheStreet assigned Dr. Reddy’s Laboratories (NYSE: RDY) a rating of “b” in a report published on Friday. This represents an improvement from their prior rating of “c+.” This data was obtained from TheStreetRatingsTable if you were wondering. RDY has also been covered in a significant number of other studies as the focus of their attention. Bloomberg previously gave Dr. Reddy’s Laboratories a “hold” rating, but it has since been changed to a “buy” recommendation in a report issued on Thursday, June 23rd. At one point, a “hold” rating had been assigned to the corporation. In a research report issued on Tuesday, the 24th of May, Barclays boosted their target price for Dr. Reddy’s Laboratories from $69.00 to $70.00. In addition, they provided the company’s stock with an “overweight” rating. Trading on the NYSE RDY got underway on Friday for $51.98 per share. While the quick to current ratio comes in at 1.41, the current to current ratio comes in at 1.98. The ratio of debt to equity is 0.001 right now. The stock price has touched $54.17, which corresponds to its 50-day simple moving average, and $54.09, which corresponds to its 200-day simple moving average. Over the previous year, Dr. Reddy’s Laboratories’ prices fluctuated between $47.28 and $67.76, with a low of $47.28 and a high of $67.76, respectively.
The firm’s market capitalization is currently sitting at $8.65 billion, while its price-to-earnings ratio stands at 22.21, its PEG ratio sits at 0.62, and its beta coefficient is 0.46. The holdings of some big investors recently underwent modifications, and RDY was the object of those moves. Envestnet Asset Management Inc. boosted the number of Dr. Reddy’s Laboratories shares it owned by 77.3% during the last three months of 2018. During the fourth quarter, American Century Companies Inc. boosted its investment in Dr. Reddy’s Laboratories by 7.1%. Since the end of the previous reporting period, Envestnet Asset Management Inc. has acquired an additional 9,800 shares, bringing its total number of shares to 22,474, each worth $1,470,000. American Century Companies Inc. now has a total of 18,821 shares following the purchase of an additional 1,250 during the most recent quarter. The value of all of the company’s shares is currently $1,231,000. NorthCrest Asset Management LLC spent approximately $754,000 during the fourth quarter to acquire a new position in Dr. Reddy’s Laboratories. This was done to take advantage of the company’s expanding business opportunities. Dimensional Fund Advisors LP boosted the amount of Dr. Reddy’s Laboratories shares that it held by 4.8% during the fourth quarter. After making an additional purchase of 26,432 shares during the most recent quarter, Dimensional Fund Advisors LP now has 581,849 shares of the company’s stock in its possession. The company’s holdings are estimated to be worth around $38,057,000. In the final quarter of 2018, BNP Paribas Arbitrage SA boosted the share of its holdings in Dr. Reddy’s Laboratories which is controlled by 87.5%. This brings us to our last point. BNP Paribas Arbitrage SA currently has 72,688 shares in the firm, having purchased an additional 33,915 shares during the most recent quarter to bring its total number to 72,688. These shares are currently worth a total of $4,755,000 as of right now. To the tune of 9.88% of the total shares outstanding, hedge funds and other types of institutional investors are the owners of these shares. Dr. Reddy’s Laboratories Limited and its various related companies worldwide are responsible for managing a pharmaceutical business. It operates in the global generics market, the pharmaceutical services and active ingredients (PSAI) industry, the proprietary products market, and other market segments to conduct its business. From a therapeutic point of view, the pharmaceutical medicines manufactured and sold by the company’s Global Generics division are regarded as the same as the company’s branded formulations. Whether the drugs are sold under a brand name or as final generic doses is true.
